» Articles » PMID: 21909419

Metformin Treatment Has No Beneficial Effect in a Dose-response Survival Study in the SOD1(G93A) Mouse Model of ALS and is Harmful in Female Mice

Overview
Journal PLoS One
Date 2011 Sep 13
PMID 21909419
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by selective degeneration of upper and lower motor neurons. The primary triggers for motor neuron degeneration are unknown but inflammation, oxidative stress and mitochondrial defects have been identified as potential contributing factors. Metformin is an anti-type II diabetes drug that has anti-inflammatory and anti-oxidant properties, can bring about mitochondrial biogenesis and has been shown to attenuate pathology in mouse models of Huntington's disease and multiple sclerosis. We therefore hypothesized that it might increase survival in the SOD1(G93A) murine model of ALS.

Methodology/principal Findings: Treatment of male and female SOD1(G93A) mice (n = ≥6 per sex) with 2 mg/ml metformin in the drinking water from 35 days, resulted in a significant increase in motor unit survival, as measured by in vivo electrophysiology at 100 days, in male EDL muscles (24+/-2 vs. 14+/-2 motor units, p<0.005) and female TA muscles (21+/-1 vs. 15+/-2 motor units, P = 0.0134). We therefore continued to test the effect of 0.5, 2 and 5 mg/ml metformin in the drinking water from 35 days on disease onset and progression (identified by twice weekly determination of weight and neurological score) as well as survival in male and female SOD1(G93A) mice (n = ≥14 per sex). Results for all groups were compared using Kaplan-Meier time to event analyses. In this survival study, metformin was unable to reduce pathology at any dose and had an unexpected dose-dependent negative effect on the onset of neurological symptoms (P = 0.0236) and on disease progression (P = 0.0362) in female mice.

Conclusions/significance: This study suggests that metformin is a poor candidate for clinical trial in ALS patients and that the possibility of harmful effects of metformin in female ALS patients with type II diabetes should be investigated.

Citing Articles

Sephin1 suppresses ER stress-induced cell death by inhibiting the formation of PP2A holoenzyme.

Gojo S, Kami D, Sano A, Teruyama F, Ogata T, Matoba S Cell Death Dis. 2025; 16(1):117.

PMID: 39971896 PMC: 11840111. DOI: 10.1038/s41419-025-07450-1.


Associations Between Diabetes Mellitus and Neurodegenerative Diseases.

Szablewski L Int J Mol Sci. 2025; 26(2).

PMID: 39859258 PMC: 11765393. DOI: 10.3390/ijms26020542.


Genetic Variation in Targets of Antidiabetic Drugs and Amyotrophic Lateral Sclerosis Risk.

Wan M, Zhang L, Huo J, Fu Y, Huang T, Fan D Biomedicines. 2025; 12(12.

PMID: 39767639 PMC: 11726913. DOI: 10.3390/biomedicines12122733.


HDAC6 inhibition as a mechanism to prevent neurodegeneration in the mSOD1 mouse model of ALS.

Phipps A, Dwyer S, Collins J, Kabir F, Atkinson R, Chowdhury M Heliyon. 2024; 10(14):e34587.

PMID: 39130445 PMC: 11315133. DOI: 10.1016/j.heliyon.2024.e34587.


Radioprotective effect of the anti-diabetic drug metformin.

Siteni S, Barron S, Luitel K, Shay J PLoS One. 2024; 19(7):e0307598.

PMID: 39042641 PMC: 11265658. DOI: 10.1371/journal.pone.0307598.


References
1.
Matthews J, Altman D, Campbell M, Royston P . Analysis of serial measurements in medical research. BMJ. 1990; 300(6719):230-5. PMC: 1662068. DOI: 10.1136/bmj.300.6719.230. View

2.
Hegedus J, Putman C, Tyreman N, Gordon T . Preferential motor unit loss in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis. J Physiol. 2008; 586(14):3337-51. PMC: 2538809. DOI: 10.1113/jphysiol.2007.149286. View

3.
Hegedus J, Putman C, Gordon T . Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2007; 28(2):154-64. DOI: 10.1016/j.nbd.2007.07.003. View

4.
Gould T, Buss R, Vinsant S, Prevette D, Sun W, Knudson C . Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci. 2006; 26(34):8774-86. PMC: 6674380. DOI: 10.1523/JNEUROSCI.2315-06.2006. View

5.
Cho Y, Kieffer T . New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia. 2010; 54(2):219-22. DOI: 10.1007/s00125-010-1986-3. View